Researchers unveiled a new combination immunotherapy that significantly boosts the immune response in patients with malignant gliomas. By integrating a personalized dendritic cell vaccine with poly-ICLC, an immune-boosting agent, the therapy has shown promise in enhancing the dendritic cells' capacity to combat this aggressive brain tumor.
Researchers unveiled a new combination immunotherapy that significantly boosts the immune response in patients with malignant gliomas. By integrating a personalized dendritic cell vaccine with poly-ICLC, an immune-boosting agent, the therapy has shown promise in enhancing the dendritic cells' capacity to combat this aggressive brain tumor.
Share this Article
Recommended